1	STATE OF OKLAHOMA
2	1st Session of the 60th Legislature (2025)
3	SENATE BILL 789 By: Gollihare
4	
5	
6	AS INTRODUCED
7	An Act relating to pharmacy benefit managers;
8	amending 59 O.S. 2021, Sections 356.2, as amended by Section 2, Chapter 332, O.S.L. 2024, 357, as amended
9	by Section 4, Chapter 332, O.S.L. 2024, and 360, as amended by Section 6, Chapter 332, O.S.L. 2024 (59
10	O.S. Supp. 2024, Sections 356.2, 357, and 360), which relate to pharmacy audit requirements, definitions,
11	and contractual duties to provider; permitting use of certain records without limitations of date or source
12	for certain purposes; modifying definitions; updating statutory language; prohibiting certain network
13	sharing; establishing certain reimbursement rates for certain drugs; providing for fee increase;
14	prohibiting certain contracts between certain parties; establishing penalties; disallowing
15	contracts from violating certain provisions; and providing an effective date.
16	
17	
18	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
19	SECTION 1. AMENDATORY 59 O.S. 2021, Section 356.2, as
20	amended by Section 2, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024,
21	Section 356.2), is amended to read as follows:
22	Section 356.2. A. The entity conducting an audit of a pharmacy
23	shall:
24	

Identify and specifically describe the audit and appeal
 procedures in the pharmacy contract. Prescription claim
 documentation and record-keeping requirements shall not exceed the
 requirements set forth by the Oklahoma Pharmacy Act or other
 applicable state or federal laws or regulations;

6 2. Give the pharmacy written notice by certified letter to the 7 pharmacy and the pharmacy's contracting agent, including 8 identification of specific prescription numbers and fill dates to be 9 audited, at least fourteen (14) calendar days prior to conducting 10 the audit, including, but not limited to, an on-site audit, a desk 11 audit, or a wholesale purchase audit, request for documentation 12 related to the dispensing of a prescription drug or any reimbursed 13 activity by a pharmacy provider; provided, however, that wholesale 14 purchase audits shall require a minimum of thirty (30) calendar 15 days' written notice. For an on-site audit, the audit date shall be 16 the date the on-site audit occurs. For all other audit types, the 17 audit date shall be the date the pharmacy provides the documentation 18 requested in the audit notice. The pharmacy shall have the 19 opportunity to reschedule the audit no more than seven (7) calendar 20 days from the date designated on the original audit notification;

3. Not interfere with the delivery of pharmacist services to a patient and shall utilize every reasonable effort to minimize inconvenience and disruption to pharmacy operations during the audit process;

Req. No. 700

4. Conduct any audit involving clinical or professional
 judgment by means of or in consultation with a licensed pharmacist;

3 5. Not consider as fraud any clerical or record-keeping error, 4 such as a typographical error, scrivener's error or computer error, 5 including, but not limited to, a miscalculated day supply, 6 incorrectly billed prescription written date or prescription origin 7 code, and such errors shall not be subject to recoupment. The 8 pharmacy shall have the right to submit amended claims 9 electronically to correct clerical or record-keeping errors in lieu 10 of recoupment. To the extent that an audit results in the 11 identification of any clerical or record-keeping errors such as 12 typographical errors, scrivener's errors or computer errors in a 13 required document or record, the pharmacy shall not be subject to 14 recoupment of funds by the pharmacy benefits manager unless the 15 pharmacy benefits manager can provide proof of intent to commit 16 fraud. A person shall not be subject to criminal penalties for 17 errors provided for in this paragraph without proof of intent to 18 commit fraud;

19 6. Permit a pharmacy to use the records of a hospital, 20 physician, or other authorized practitioner of the healing arts for 21 drugs or medicinal supplies written or transmitted by any means of 22 communication for purposes of validating the pharmacy record with 23 respect to orders or refills of a legend or narcotic drug;

24

1 7. Permit a pharmacy to use drug purchase records without 2 limitation of date or source to validate the dispensing of a 3 prescription drug or a controlled dangerous substance, provided the 4 drug purchase was done in accordance with state or federal law; 5 8. Not include the dispensing fee amount or the actual invoice 6 cost of the prescription dispensed in a finding of an audit 7 recoupment unless a prescription was not actually dispensed or a 8 physician denied authorization of a dispensing order; 9 8. 9. Audit each pharmacy under identical standards, regularity 10 and parameters as other similarly situated pharmacies and all 11 pharmacies owned or managed by the pharmacy benefits manager 12 conducting or having conducted the audit; 13 9. 10. Not exceed one (1) year from the date the claim was 14 submitted to or adjudicated by a managed care company, nonprofit 15 hospital or medical service organization, insurance company, third-16 party payor, pharmacy benefits manager, a health program 17 administered by a department of this state, or any entity that 18 represents the companies, groups, or departments for the period 19 covered by an audit; 20 10. 11. Not schedule or initiate an audit during the first

21 seven (7) calendar days of any month unless otherwise consented to 22 by the pharmacy;

23 <u>11. 12.</u> Disclose to any plan sponsor whose claims were included 24 in the audit any money recouped in the audit;

Req. No. 700

\_ \_

<sup>1</sup> 12. <u>13.</u> Not require pharmacists to break open packaging labeled <sup>2</sup> "for single-patient-use only". Packaging labeled "for single-<sup>3</sup> patient-use only" shall be deemed to be the smallest package size <sup>4</sup> available; and

<sup>5</sup> <u>13. 14.</u> Upon recoupment of funds from a pharmacy, refund first <sup>6</sup> to the patient the portion of the recovered funds that were <sup>7</sup> originally paid by the patient, provided such funds were part of the <sup>8</sup> recoupment.

9 Any entity that conducts wholesale purchase review В. 1. 10 during an audit of a pharmacist or pharmacy shall not require the 11 pharmacist or pharmacy to provide a full dispensing report. 12 Wholesaler invoice reviews shall be limited to verification of 13 purchase inventory specific to the pharmacy claims paid by the 14 health benefits plan or pharmacy benefits manager conducting the 15 audit without limitation to date or source of purchase.

16 2. Any entity conducting an audit shall not identify or label a 17 prescription claim as an audit discrepancy when:

- a. the National Drug Code for the dispensed drug is in a
   quantity that is a subunit or multiple of the drug
   purchased by the pharmacist or pharmacy as supported
   by a wholesale invoice,
- b. the pharmacist or pharmacy dispensed the correct
  quantity of the drug according to the prescription,
  and

Req. No. 700

\_ \_

1 the drug dispensed by the pharmacist or pharmacy с. 2 shares all but the last two digits of the National 3 Drug Code of the drug reflected on the supplier 4 invoice. 5 An entity conducting an audit shall accept as evidence, 3. 6 without limitation on date or source of purchase subject to 7 validation, to support the validity of a pharmacy claim related to a 8 dispensed drug: 9 redacted copies of supplier invoices in the a. 10 pharmacist's or pharmacy's possession, or 11 invoices and any supporting documents from any b. 12 supplier as authorized by federal or state law to 13 transfer ownership of the drug acquired by the 14 pharmacist or pharmacy. 15 4. An entity conducting an audit shall provide, no later than 16 five (5) calendar days after the date of a request by the pharmacist 17 or pharmacy, all supporting documents the pharmacist's or pharmacy's 18 purchase suppliers provided to the health benefits plan issuer or 19 pharmacy benefits manager. 20 C. A pharmacy shall be allowed to provide the pharmacy's

21 computerized patterned medical records or the records of a hospital, 22 physician, or other authorized practitioner of the healing arts for 23 drugs or medicinal supplies written or transmitted by any means of

<sup>1</sup> communication for purposes of supporting the pharmacy record with <sup>2</sup> respect to orders or refills of a legend or narcotic drug.

3 D. The entity conducting the audit shall not audit more than 4 fifty prescriptions, with specific date of service, per calendar 5 The annual limit to the number of prescription claims audited year. 6 shall be inclusive of all audits, including any prescription-related 7 documentation requests from the health insurer, pharmacy benefits 8 manager or any third-party company conducting audits on behalf of 9 any health insurer or pharmacy benefits manager during a calendar 10 year.

E. If paper copies of records are requested by the entity conducting the audit, the entity shall pay twenty-five cents (\$0.25) per page to cover the costs incurred by the pharmacy. The entity conducting the audit shall provide the pharmacy with accurate instructions, including any required form for obtaining reimbursement for the copied records.

F. The entity conducting the audit shall:

18 1. Deliver a preliminary audit findings report to the pharmacy 19 and the pharmacy's contracting agent within forty-five (45) calendar 20 days of conducting the audit;

21 2. Allow the pharmacy at least ninety (90) calendar days 22 following receipt of the preliminary audit findings report in which 23 to produce documentation to address any discrepancy found during the 24

1 audit; provided, however, a pharmacy may request an extension, not 2 to exceed an additional forty-five (45) calendar days;

3 3. Deliver a final audit findings report to the pharmacy and 4 the pharmacy's contracting agent signed by the auditor within ten 5 (10) calendar days after receipt of additional documentation 6 provided by the pharmacy, as provided for in Section 356.3 of this 7 title;

Allow the pharmacy to reverse and resubmit claims
 electronically within thirty (30) calendar days of receipt of the
 final audit report in lieu of the auditing entity recouping
 discrepant claim amounts from the pharmacy;

12 5. Not recoup any disputed funds until after final disposition 13 of the audit findings, including the appeals process as provided for 14 in Section 356.3 of this title; and

6. Not accrue interest during the audit and appeal period.

16 G. Each entity conducting an audit shall provide a copy of the 17 final audit results, and a final audit report upon request, after 18 completion of any review process to the plan sponsor.

H. 1. The full amount of any recoupment on an audit shall be
 refunded to the plan sponsor. Except as provided for in paragraph 2
 of this subsection, a charge or assessment for an audit shall not be
 based, directly or indirectly, on amounts recouped.

23 2. This subsection does not prevent the entity conducting the 24 audit from charging or assessing the responsible party, directly or

15

1 indirectly, based on amounts recouped if both of the following
2 conditions are met:

a. the plan sponsor and the entity conducting the audit
have a contract that explicitly states the percentage
charge or assessment to the plan sponsor, and
b. a commission to an agent or employee of the entity
conducting the audit is not based, directly or
indirectly, on amounts recouped.

9 I. Unless superseded by state or federal law, auditors shall 10 only have access to previous audit reports on a particular pharmacy 11 conducted by the auditing entity for the same pharmacy benefits 12 manager, health plan or insurer. An auditing vendor contracting 13 with multiple pharmacy benefits managers or health insurance plans 14 shall not use audit reports or other information gained from an 15 audit on a pharmacy to conduct another audit for a different 16 pharmacy benefits manager or health insurance plan.

J. Sections A through I of this section shall not apply to any audit initiated based on or that involves fraud, willful misrepresentation, or abuse.

20 K. If the Attorney General, after notice and opportunity for 21 hearing, finds that the entity conducting the audit failed to follow 22 any of the requirements pursuant to the Pharmacy Audit Integrity 23 Act, the audit shall be considered null and void. Any monies 24 recouped from a null and void audit shall be returned to the

Req. No. 700

\_ \_

<sup>1</sup> affected pharmacy within fourteen (14) calendar days. Any violation <sup>2</sup> of this section by a pharmacy benefits manager or auditing entity <sup>3</sup> shall be deemed a violation of the Pharmacy Audit Integrity Act. <sup>4</sup> SECTION 2. AMENDATORY 59 O.S. 2021, Section 357, as <sup>5</sup> amended by Section 4, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024, <sup>6</sup> Section 357), is amended to read as follows:

<sup>7</sup> Section 357. A. As used in Sections 357 through 360 of this <sup>8</sup> title:

9 1. "Covered entity" means a nonprofit hospital or medical 10 service organization, for-profit hospital or medical service 11 organization, insurer, health benefit plan, health maintenance 12 organization, health program administered by the state in the 13 capacity of providing health coverage, or an employer, labor union, 14 or other group of persons that provides health coverage to persons 15 in this state. This term does not include a health benefit plan 16 that provides coverage only for accidental injury, specified 17 disease, hospital indemnity, disability income, or other limited 18 benefit health insurance policies and contracts that do not include 19 prescription drug coverage;

20 2. "Covered individual" means a member, participant, enrollee, 21 contract holder or policy holder or beneficiary of a covered entity 22 who is provided health coverage by the covered entity. A covered 23 individual includes any dependent or other person provided health

24

1 coverage through a policy, contract or plan for a covered 2 individual;

3. "Department" means the Insurance Department;

4 4. <u>"Effective rate contracting" means any agreement or</u>
5 <u>arrangement between a pharmacy or contracting agent acting on behalf</u>
6 <u>of a pharmacy and a pharmacy benefits manager for pharmaceuticals</u>
7 <u>based on the effective rate of payment rather than a predetermined</u>
8 fixed price or fixed discount percentage;

9 <u>5.</u> "Maximum allowable cost", "MAC", or "MAC list" means the 10 list of drug products delineating the maximum per-unit reimbursement 11 for multiple-source prescription drugs, medical product, or device;

<sup>12</sup> <u>5. 6.</u> "Multisource drug product reimbursement" (reimbursement) <sup>13</sup> means the total amount paid to a pharmacy inclusive of any reduction <sup>14</sup> in payment to the pharmacy, excluding prescription dispense fees <u>and</u> <sup>15</sup> professional fees;

6. 7. "Office" means the Office of the Attorney General;

17 7. 8. "Pharmacy benefits management" means a service provided 18 to covered entities to facilitate the provision of prescription drug 19 benefits to covered individuals within the state, including 20 negotiating pricing and other terms with drug manufacturers and 21 providers. Pharmacy benefits management may include any or all of 22 the following services:

23

16

- 24
- ᅩᄀ

- 1 a. claims processing, retail network management and 2 payment of claims to pharmacies for prescription drugs 3 dispensed to covered individuals,
  - b. clinical formulary development and management services, or

c. rebate contracting and administration;

7 8. 9. "Pharmacy benefits manager" or "PBM" means a person, 8 business, or other entity that performs pharmacy benefits 9 management. The term shall include a person or entity acting on 10 behalf of a PBM in a contractual or employment relationship in the 11 performance of pharmacy benefits management for a managed care 12 company, nonprofit hospital, medical service organization, insurance 13 company, third-party payor, or a health program administered by an 14 agency or department of this state;

<sup>15</sup> <u>9. 10.</u> "Plan sponsor" means the employers, insurance companies, <sup>16</sup> unions and health maintenance organizations or any other entity <sup>17</sup> responsible for establishing, maintaining, or administering a health <sup>18</sup> benefit plan on behalf of covered individuals; and

<sup>19</sup> 10. <u>11.</u> "Provider" means a pharmacy licensed by the State Board <sup>20</sup> of Pharmacy, or an agent or representative of a pharmacy, including, <sup>21</sup> but not limited to, the pharmacy's contracting agent, which <sup>22</sup> dispenses prescription drugs or devices to covered individuals.

B. Nothing in the definition of pharmacy benefits management or pharmacy benefits manager in the Patient's Right to Pharmacy Choice

4

5

Act, Pharmacy Audit Integrity Act, or Sections 357 through 360 of this title shall deem an employer a "pharmacy benefits manager" of its own self-funded health benefit plan, except, to the extent permitted by applicable law, where the employer, without the tilization of a third party and unrelated to the employer's own pharmacy:

7 negotiates directly with drug manufacturers, a. 8 b. processes claims on behalf of its members, or 9 manages its own retail network of pharmacies. с. 10 SECTION 3. AMENDATORY 59 O.S. 2021, Section 360, as 11 amended by Section 6, Chapter 332, O.S.L. 2024 (59 O.S. Supp. 2024, 12 Section 360), is amended to read as follows:

Section 360. A. The pharmacy benefits manager shall, with respect to contracts between a pharmacy benefits manager and a provider, including a pharmacy service administrative organization:

16 1. Include in such contracts the specific sources utilized to 17 determine the maximum allowable cost (MAC) pricing of the pharmacy, 18 update MAC pricing at least every seven (7) calendar days, and 19 establish a process for providers to readily access the MAC list 20 specific to that provider;

21 2. In order to place a drug on the MAC list, ensure that the 22 drug is listed as "A" or "B" rated in the most recent version of the 23 FDA's Approved Drug Products with Therapeutic Equivalence 24 Evaluations, also known as the Orange Book, and the drug is

Req. No. 700

1 generally available for purchase by pharmacies in the state from 2 national or regional wholesalers and is not obsolete;

3 3. Ensure dispensing fees are not included in the calculation
4 of MAC price reimbursement to pharmacy providers;

5 4. Provide a reasonable administration appeals procedure to 6 allow a provider, a provider's representative and a pharmacy service 7 administrative organization to contest reimbursement amounts within 8 fourteen (14) calendar days of the final adjusted payment date. The 9 pharmacy benefits manager shall not prevent the pharmacy or the 10 pharmacy service administrative organization from filing 11 reimbursement appeals in an electronic batch format. The pharmacy 12 benefits manager must respond to a provider, a provider's 13 representative and a pharmacy service administrative organization 14 who have contested a reimbursement amount through this procedure 15 within ten (10) calendar days. The pharmacy benefits manager must 16 respond in an electronic batch format to reimbursement appeals filed 17 in an electronic batch format. The pharmacy benefits manager shall 18 not require a pharmacy or pharmacy services administrative 19 organization to log into a system to upload individual claim appeals 20 or to download individual appeal responses. If a price update is 21 warranted, the pharmacy benefits manager shall make the change in 22 the reimbursement amount, permit the dispensing pharmacy to reverse 23 and rebill the claim in question, and make the reimbursement amount 24 change retroactive and effective for all contracted providers; and

-

\_ \_

Req. No. 700

1 5. If a below-cost reimbursement appeal is denied, the PBM 2 shall provide the reason for the denial, including the National Drug 3 Code (NDC) number from, and the name of, the specific national or 4 regional wholesalers doing business in this state where the drug is 5 currently in stock and available for purchase by the dispensing 6 pharmacy at a price below the PBM's reimbursement price. If the NDC 7 number provided by the pharmacy benefits manager is not available 8 below the acquisition cost obtained from the pharmaceutical 9 wholesaler from whom the dispensing pharmacy purchases the majority 10 of the prescription drugs that are dispensed, the pharmacy benefits 11 manager shall immediately adjust the reimbursement amount, permit 12 the dispensing pharmacy to reverse and rebill the claim in question, 13 and make the reimbursement amount adjustment retroactive and 14 effective in effect for all contracted providers for future claims 15 billed. 16 Β. The reimbursement appeal requirements in this section shall 17 apply to all drugs, medical products, or devices reimbursed 18 according to any payment methodology, including, but not limited to:

Average acquisition cost, including the National Average
 Drug Acquisition Cost;

2. Average manufacturer price;

22 3. Average wholesale price;

Brand effective rate or generic effective rate;

24 5. Discount indexing;

Req. No. 700

21

\_ \_

1

2

4

6. Federal upper limits;

7. Wholesale acquisition cost; and

3 8. Any other term that a pharmacy benefits manager or an insurer of a health benefit plan may use to establish reimbursement 5 rates to a pharmacist or pharmacy for pharmacist services.

6 С. The pharmacy benefits manager shall not place a drug on a 7 MAC list, unless there are at least two therapeutically equivalent, 8 multiple-source drugs, generally available for purchase by 9 dispensing retail pharmacies from national or regional wholesalers.

10 In the event that a drug is placed on the FDA Drug Shortages D. 11 Database, pharmacy benefits managers shall reimburse claims to 12 pharmacies at no less than the wholesale acquisition cost for the 13 specific NDC number being dispensed.

14 The pharmacy benefits manager shall not require Ε. 15 accreditation or licensing of providers, or any entity licensed or 16 regulated by the State Board of Pharmacy, other than by the State 17 Board of Pharmacy or federal government entity as a condition for 18 participation as a network provider.

19 A pharmacy or pharmacist may decline to provide the F. 20 pharmacist clinical or dispensing services to a patient or pharmacy 21 benefits manager if the pharmacy or pharmacist is to be paid less 22 than the pharmacy's cost for providing the pharmacist clinical or 23 dispensing services.

24 \_ \_

1	G. The pharmacy benefits manager shall provide a dedicated
2	telephone number, email address and names of the personnel with
3	decision-making authority regarding MAC appeals and pricing.
4	H. No pharmacy benefits manager (PBM) shall lease, rent, or
5	otherwise make its provider network available to another pharmacy
6	benefits manager. Prohibited activities shall include, but not be
7	limited to:
8	1. Entering into agreements or contracts that allow another PBM
9	to use the provider network; and
10	2. Facilitating access to the provider network though any form
11	of leasing or renting arrangement.
12	I. The PBM shall, with respect to contracts between a PBM and a
13	provider, including contracts with pharmacy service administrative
14	organization, ensure that reimbursement to pharmacies for each drug
15	dispensed is no less than one hundred six percent (106%) of the
16	National Average Drug Acquisition Cost (NADAC) plus a professional
17	fee of Fifteen Dollars (\$15.00). The NADAC price shall be the price
18	published in effect for the date the drug claim was billed by the
19	pharmacy. If a particular drug does not have a published NADAC
20	price, the reimbursement shall be one hundred ten percent (110%) of
21	the wholesale acquisition cost (WAC) plus a professional fee of
22	Fifteen Dollars (\$15.00) for generic drugs and one hundred (100%)
23	percent of the WAC plus a professional fee of Fifteen Dollars
24	(\$15.00) for brand-name drugs. The professional fee shall

1	automatically increase on January 1 of each year at a percentage
2	equal to the inflation rate measured by the Consumer Price Index for
3	the previous twelve-month period.
4	J. 1. Effective rate contracting is hereby prohibited in all
5	agreements between pharmacies or contracting agents acting on behalf
6	of a pharmacy and a PBM or third-party payers. No PBM or third-
7	party payer shall enter into any contract that establishes payment
8	for services or medications based on an effective rate of
9	reimbursement.
10	2. Any PBM or third-party payer found to be in violation of
11	this section shall be subject to penalties, including, but not
12	limited to, fines, revocation of licensure, or other disciplinary
13	actions.
14	K. The provisions of this section shall not be waived, voided,
15	or nullified by contract.
16	SECTION 4. This act shall become effective November 1, 2025.
17	
18	60-1-700 CAD 1/19/2025 5:43:20 AM
19	
20	
21	
22	
23	
24	
<b>۲</b> ک	